Breaks Categories: News

ThursdayMay 05, 2022 2:55 pm

PsychedelicNewsBreaks – Pasithea Therapeutics Corp.’s (NASDAQ: KTTA) CEO Featured in Forbes Article

Pasithea Therapeutics’ (NASDAQ: KTTA) CEO, Dr. Tiago Reis Marques, a psychiatrist at one of the top psychiatry centers in the world, a fellow at Imperial College London and a lecturer at the Institute of Psychiatry, King’s College London, was featured in a recent Forbes article. The piece, titled “You May Soon Find Mental Health Help from Psychedelic Drug-Assisted Psychotherapy in the Metaverse,” discusses record levels of mental health issues driven by the pandemic, social unrest, partisan politics, cable news, social media and Russia’s war against Ukraine. To learn about ways to help with this mental health epidemic, the article’s author…

Continue Reading

ThursdayMay 05, 2022 12:45 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO Featured on Success Story Podcast

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and its cofounder and CEO Matt Stang were spotlighted in a recent episode of The Success Story podcast. During the interview, Stang talked all things Delic, including a history of the company, his decision to pivot from a career in cannabis to psychedelics, and what he believes the future holds for the company. “When we created [Delic], it was really under the supposition that a tipping point was coming for psychedelics the way it had come for cannabis,” said Delic Holdings…

Continue Reading

ThursdayMay 05, 2022 12:34 pm

PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Preclinical Study Findings to Be Showcased at Global Event Focused on Psychedelic-Assisted Therapy

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that an abstract highlighting preclinical data for its deuterated psilocybin analog CYB003 has been selected for a poster presentation at the “From Research to Reality” Global Summit on Psychedelic-Assisted Therapies and Medicines. The event is slated to take place from May 27-29, 2022, in Toronto, Canada. “It is an honor to participate in this inaugural conference devoted to psychedelic-assisted therapy and to be part of the rigorous scientific work being done in the field,” said Doug Drysdale, chief executive officer of Cybin. “The…

Continue Reading

WednesdayMay 04, 2022 2:55 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Ketamine Wellness Centers Now Offer NAD+ Infusion Therapy

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and its Ketamine Wellness Centers (“KWC”)  are now offering  NAD+ infusion therapy at six clinic locations. KWC is the largest ketamine therapy provider in the country to offer the therapy, which is administered intravenously or intramuscularly. According to the company, the treatment can boost natural energy stores and immunity, along with brain and DNA function as well as cell communication; the treatment can also facilitate the healing chronic conditions such as depression, PTSD and anxiety. The treatment will be available at…

Continue Reading

ThursdayApr 28, 2022 11:28 am

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) to Participate in Upcoming Planet MicroCap Showcase

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, will be presenting at this year’s Planet MicroCap Showcase; the event is scheduled for May 3–5, 2022. During the showcase, Delic Holdings cofounder and CEO Matt Stang will be sharing an overview of the company, including details about business expectations and growth opportunities; his discussion, slated for May 4, will also include a look at the company’s strategic plans for the remainder of this year. The premier in-person microCap finance event, the Planet MicroCap Showcase is held in Las Vegas and…

Continue Reading

FridayApr 22, 2022 10:47 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at KCSA Psychedelics Virtual Investor Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its CEO Doug Drysdale will present at the KCSA Psychedelics Virtual Investor Conference. Drysdale’s presentation is slated to begin at 11:00 a.m. ET on Thursday, April 28, 2022, at the live, interactive online event designed to invite investors to ask the company questions in real-time. Interested parties should visit https://ibn.fm/2G8rh to register for the conference and access the webcast. The archived webcast will also be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/OYUat About Cybin…

Continue Reading

ThursdayApr 21, 2022 1:47 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Strategic Advisory Board Appointments

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A),a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the appointment of David Allan and John McGraw, PhD, MSc, to the company’s advisory board. Allan is the 2017 recipient of the prestigious Julia Levy Award and will collaborate with 2021 Julia Levy Award winner Dr. Lakshmi P. Kotra, CEO of FSD Pharma subsidiary Lucid Psycheceuticals. McGraw has more than 20 years of executive experience commercializing health technologies, including medical devices, therapeutics and health services. “Mr. Allan and Dr. McGraw both have impressive careers in the…

Continue Reading

ThursdayApr 21, 2022 1:14 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Work with Clinilabs on Phase 1/2a Trial Focused on CYB003 for MDD Treatment

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has partnered with Clinilabs Drug Development Corporation to work on its upcoming phase 1/2a clinical trial of CYB003. Clinilabs is a global, full-service contract research organization that has built a reputation for its expertise in central nervous system drug development. Derived from psilocybin, Cybin’s CYB003 is part of a family of molecules called indolamines that include common neurotransmitters such as serotonin. The molecule will be the first psilocybin analog to be evaluated in phase 1/2a development for the treatment of major depressive disorder (“MDD”). According to…

Continue Reading

WednesdayApr 20, 2022 11:47 am

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Produces First Batch of SPU-21 Liposomes for RA Study

Silo Pharma (OTCQB: SILO) is a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic. The company today announced that it has produced its first batch of liposomes for use in a preclinical study that will be conducted by Frontage Laboratories, a CRO (contract research organization). According to the update, the ability of the SPU-21 to target inflamed epithelium suggest their potential use to target drug delivery. Silo’s novel joint homing peptides can be used to treat autoimmune diseases, which include but are not limited to rheumatoid arthritis (“RA”). This approach could enhance the therapeutic effect of…

Continue Reading

TuesdayApr 19, 2022 1:39 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) to Participate at Sequire Cannabis and Psychedelic Conference, Scottsdale Capital Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that its co-founder and CEO Matt Stang will participate at the Sequire Cannabis and Psychedelic Conference and the Scottsdale Capital Event. Stang will present the company's performance and industry outlook and participate in one-on-one meetings with investors at the Sequire Cannabis and Psychedelic Conference. The virtual event, taking place on April 20, 2022, will bring together over 50 leading public companies in the cannabis, CBD and psychedelic space to discuss the future of their respective industries. In addition, Stang…

Continue Reading